Presented By Dong-Wan Kim at 2014 ASCO Annual Meeting

Presented By Dong-Wan Kim at 2014 ASCO Annual Meeting

Clinical activity and safety of HM61713, <br />an EGFR mutant selective inhibitor, in advanced<br />non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had
received<br />EGFR tyrosine kinase inhibitors (TKIs)
Presented By Dong-Wan Kim at 2014 ASCO Annual Meeting
Backgrounds
Presented By Dong-Wan Kim at 2014 ASCO Annual Meeting
HM61713
Presented By Dong-Wan Kim at 2014 ASCO Annual Meeting
Study Design
Presented By Dong-Wan Kim at 2014 ASCO Annual Meeting
Patient Characteristics (1)
Presented By Dong-Wan Kim at 2014 ASCO Annual Meeting
Patient Characteristics (2)
Presented By Dong-Wan Kim at 2014 ASCO Annual Meeting
Pharmacokinetics
Presented By Dong-Wan Kim at 2014 ASCO Annual Meeting
Adverse Event (≥10% of patients)
Presented By Dong-Wan Kim at 2014 ASCO Annual Meeting
Lab Abnormality (≥3% of patients)
Presented By Dong-Wan Kim at 2014 ASCO Annual Meeting
Dose Limiting Toxicities
Presented By Dong-Wan Kim at 2014 ASCO Annual Meeting
Best Change from Baseline in Target Lesions<br />: Expansion part
Presented By Dong-Wan Kim at 2014 ASCO Annual Meeting
Slide 12
Presented By Dong-Wan Kim at 2014 ASCO Annual Meeting
Best Change from Baseline in Target Lesions<br />: T790M+ versus T790M-
Presented By Dong-Wan Kim at 2014 ASCO Annual Meeting
Best Overall Response: Expansion Part
Presented By Dong-Wan Kim at 2014 ASCO Annual Meeting
Duration of Treatment: Expansion Part
Presented By Dong-Wan Kim at 2014 ASCO Annual Meeting
Progression-Free Survival<br />: Expansion part (T790M+ versus T790M-)
Presented By Dong-Wan Kim at 2014 ASCO Annual Meeting
Conclusions
Presented By Dong-Wan Kim at 2014 ASCO Annual Meeting
Future Plan
Presented By Dong-Wan Kim at 2014 ASCO Annual Meeting
Acknowledgements
Presented By Dong-Wan Kim at 2014 ASCO Annual Meeting